Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy

Sheng-Fa Su, Fei Han, Chong Zhao, Ying Huang, Chun-Yan Chen, Wei-Wei Xiao, Jia-Xin Li, Tai-Xiang Lu, Sheng-Fa Su, Fei Han, Chong Zhao, Ying Huang, Chun-Yan Chen, Wei-Wei Xiao, Jia-Xin Li, Tai-Xiang Lu

Abstract

Although many studies have investigated intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC), sample sizes in the reported studies are usually small and different in outcomes in different T and N subgroups are seldom analyzed. Herein, we evaluated the outcomes of NPC patients treated with IMRT and further explored treatment strategy to improve such outcome. We collected clinical data of 865 NPC patients treated with IMRT alone or in combination with chemotherapy, and classified all cases into the following prognostic categories according to different TNM stages: early stage group (T1-2N0-1M0), advanced local disease group (T3-4N0-1M0), advanced nodal disease group (T1-2N2-3M0), and advanced locoregional disease group (T3-4N2-3M0). The 5-year overall survival (OS), local relapse-free survival (LRFS), and distant metastases-free survival (DMFS) were 83.0%, 90.4%, and 84.0%, respectively. The early disease group had the lowest treatment failure rate, with a 5-year OS of 95.6%. The advanced local disease group and advanced nodal disease group had similar failure pattern and treatment outcomes as well as similar hazard ratios for death (4.230 and 4.625, respectively). The advanced locoregional disease group had the highest incidence of relapse and death, with a 5-year DMFS and OS of 62.3% and 62.2%, respectively, and a hazard ratio for death of 10.402. Comparing with IMRT alone, IMRT in combination with chemotherapy provided no significant benefit to locoregionally advanced NPC. Our results suggest that the decision of treatment strategy for NPC patients should consider combinations of T and N stages, and that IMRT alone for early stage NPC patients can produce satisfactory results. However, for advanced local, nodal, and locoregional disease groups, a combination of chemotherapy and radiotherapy is recommended.

Figures

Figure 1.. Risk ratios of death in…
Figure 1.. Risk ratios of death in patients with different T and N stage nasopharyngeal careinoma (NPC).
Figure 2.. Local recurrence-free survival curves (A),…
Figure 2.. Local recurrence-free survival curves (A), regional recurrence-free survival curves (B), progression-free survival curves (C), distant metastasis-free survival curves (D), and overall survival curves (E) of NPC patients in different subgroups.

References

    1. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China [J] Chin J Cancer. 2011;30(2):114–119.
    1. Trejaut J, Lee CL, Yen JC, et al. Ancient migration routes of Austronesian-speaking populations in oceanic Southeast Asia and Melanesia might minic the spread of nasopharyngeal carcinoma [J] Chin J Cancer. 2011;30(2):96–105.
    1. Xiao WW, Han F, Lu TX, et al. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma [J] Int J Radiat Oncol Biol Phys. 2009;74(4):1070–1076.
    1. Song CH, Wu HG, Heo DS, et al. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma [J] Laryngoscope. 2008;118(4):663–670.
    1. Chua DT, Sham JS, Kwong DL, et al. Treatment outcome after radiotherapy alone for patients with Stage I–II nasopharyngeal carcinoma [J] Cancer. 2003;98(1):74–80.
    1. Chen CY, Han F, Zhao C, et al. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone [J] Br J Radiol. 2009;82(978):452–458.
    1. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution [J] Int J Radiat Oncol Biol Phys. 2006;65(1):161–168.
    1. Su SF, Lu TX, Zhao C, et al. Comparison of the Chinese '92 and 2008 staging systems of nasopharyngeal carcinoma according to the long term outcomes of patients treated with intensity-modulated radiotherapy [J] Chin J Radiat Oncol. 2010;19(3):185–189. [in Chinese]
    1. Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience [J] Int J Radiat Oncol Biol Phys. 2004;60(5):1440–1450.
    1. Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma [J] Int J Radiat Oncol Biol Phys. 2010;76(1):138–145.
    1. Zhao C, Xiao WW, Han F, et al. Long-term outcome and prognostic factors of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy [J] Chin J Radiat Oncol. 2010;19(3):191–196. [in Chinese]
    1. Chen CY, Han F, Zhao C, et al. Long-term results of 934 nasopharyngeal carcinoma treated with radiotherapy alone [J] Chin J Radiat Oncol. 2008;17(6):411–415. [in Chinese]
    1. Zhang Y, Lin ZA, P JJ, et al. Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy [J] Chin J Cancer. 2009;28(11):1143–1148. [in Chinese]
    1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 [J] J Clin Oncol. 1998;16(4):1310–1317.
    1. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature [J] J Clin Oncol. 2004;22(22):4604–4612.
    1. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1528 patients from six randomized trials [J] Am J Clin Oncol. 2002;25(3):219–223.
    1. Tham IW, Lin S, Pan J, et al. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer [J] Am J Clin Oncol. 2010;33(3):294–299.
    1. Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases [J] BMC Cancer. 2010;10:39.
    1. Zhao C, Lu TX, Han F, et al. Clinical study of 139 nasopharyngeal carcinoma patients for intensity modulated radiation therapy [J] Chin J Radiat Oncol. 2006;15(1):1–6. [in Chinese]
    1. Chua DT, Sham JS, Wei WI, et al. The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma [J] Cancer. 2001;92(11):2845–2855.
    1. Tham IW, Hee SW, Yeo RM, et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre Singapore experience [J] Int J Radiat Oncol Biol Phys. 2009;75(5):1481–1486.
    1. Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group [J] Cancer. 1998;83(11):2270–2283.
    1. Zong JF, Ma J, Tang LL, et al. A study of the combined treatment strategy for patients with nasopharyngeal carcinoma based on the analysis of the treatment results from 749 cases [J] China Cancer. 2005;14(8):538–542. [in Chinese]
    1. Chua DT, Ma J, Sham JS, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials [J] Int J Radiat Oncol Biol Phys. 2006;65(5):1300–1306.
    1. Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone [J]. Int J Radiat Oncol Biol Phys. 2010 Oct 29; [Epub ahead of print]
    1. Cheng SH, Tsai SY, Yen KL, et al. Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I–III nasopharyngeal carcinoma [J] Int J Radiat Oncol Biol Phys. 2005;61(2):456–465.
    1. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience [J] Int J Radiat Oncol Biol Phys. 2002;53(1):12–22.
    1. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma [J] J Clin Oncol. 2001;19(5):1350–1357.
    1. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials [J] J Clin Oncol. 2005;23(6):1118–1124.
    1. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J] J Clin Oncol. 2004;22(13):2643–2653.
    1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J] N Engl J Med. 2006;354(6):567–578.
    1. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer [J] N Engl J Med. 2007;357(17):1695–1704.
    1. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma [J] J Clin Oncol. 2005;23(30):3568–3576.
    1. He XY, Hu CS, Ying HM, et al. Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma [J] Eur Arch Otorhinolaryngol. 2010;267(5):773–778.
    1. Kong L, Zhang YW, Hu CS, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma [J] Chin J Cancer. 2010;29(5):551–555.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren